Next-Generation Bispecific Nanobody Targeting IL23A and TNFSF15 for Inflammatory Bowel Disease

VHH-P803 is a bispecific, humanized nanobody-based antibody construct in biological testing, designed for the potential treatment of inflammatory bowel disease (IBD). This innovative molecule targets both interleukin 23 subunit alpha (IL23A) and TNF superfamily member 15 (TNFSF15), two key drivers of inflammatory signaling pathways implicated in IBD pathophysiology. By simultaneously modulating these distinct but complementary immune targets, VHH-P803 offers a promising approach to address complex immune dysregulation underlying IBD, representing a novel and versatile therapeutic strategy currently under preclinical evaluation.

Licensing Opportunity

VHH-P803 is available for out-licensing and strategic development partnerships. We welcome collaboration with industry partners to advance this innovative bispecific nanobody program toward clinical and commercial success.

Development Phase

Modality

VHH-P803 utilizes a bispecific antibody construct comprising two single-domain antibodies (nanobodies), each precisely engineered to bind and neutralize a unique target: TL1A and IL-23 p19. Nanobodies, with their exceptionally small molecular size and unique structural stability, offer enhanced tissue penetration, increased solubility, and resistance to harsh conditions typical in the inflammatory milieu of IBD. The modular nature of this structure enables simultaneous engagement of multiple disease-relevant pathways with reduced immunogenic risk, potentially translating into more effective and durable disease control in patients with inflammatory bowel disease.

Target

IL23A and TNFSF15 are pivotal targets in the immunopathology of inflammatory bowel disease. IL23A is a cytokine subunit integral to the development and maintenance of Th17 responses, while TNFSF15 is a member of the tumor necrosis factor superfamily involved in both immune cell activation and regulation of mucosal inflammation. Both IL23A and TNFSF15 are primarily expressed in cells of the intestinal mucosa and immune compartments. Dysregulation of IL23A and TNFSF15 signaling is recognized as a key pathogenic mechanism in IBD. Therefore, dual targeting of IL23A and TNFSF15 provides a strategic advantage, potentially leading to comprehensive modulation of inflammatory pathways that drive disease progression. VHH-P803's concurrent action on IL23A and TNFSF15 positions it as a unique and attractive therapeutic asset in the IBD development landscape.

Mechanism of Action

VHH-P803 operates through simultaneous antagonism of IL23A and TNFSF15, disrupting pathological cytokine signaling central to the persistence of chronic inflammation in IBD. By binding to IL23A, VHH-P803 is poised to inhibit the IL-23/Th17 inflammatory axis, thereby reducing pro-inflammatory cytokine production and immune cell recruitment. Concurrent targeting of TNFSF15 impedes additional signal transduction pathways involved in T-cell activation and mucosal immunity. This dual mechanism is designed to achieve synergistic suppression of intestinal inflammation. The nanobody platform underlying VHH-P803 also offers the versatility to be adapted for advanced therapeutic modalities, such as antibody-drug conjugates (ADCs) or next-generation bispecific formats targeting other inflammatory or immune-related diseases.

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is an umbrella term for chronic, relapsing inflammatory disorders of the gastrointestinal tract, primarily comprising Crohn’s disease and ulcerative colitis. The global disease burden of IBD has been steadily rising, posing significant healthcare challenges due to its debilitating nature and lifelong management. Standard treatment strategies include immunosuppressants, biological agents targeting various inflammatory cytokines, and in severe cases, surgical intervention. However, many patients experience partial or non-response, loss of efficacy over time, or significant treatment-related side effects. There remains a high unmet need for safer, more effective therapies that can induce and sustain remission, minimize adverse events, and address refractory cases. VHH-P803’s novel bispecific approach against IL23A and TNFSF15 offers the potential to overcome resistance mechanisms, deliver more comprehensive inflammation control, and provide an improved therapeutic option for IBD patients.